3728 Jinke Rd, Bldg 1, West Wing, Shanghai, China info@tyligand.com


Tyligand Bioscience
was founded in 2018, located in Zhangjiang Medicine Valley in Shanghai Pilot Free Trade Zone

We have an integrated 45,000 ft2 state of the art facility that houses medicinal chemistry, biological testing, ADME assessment;  process, formulation and clinical development teams to support the core IP generation research and preclinical development, IND applications, and early clinical development efforts.

Who we are

The team is dedicated to the discovery and development of innovative drugs for cancer and autoimmune diseases, leveraging deep knowledge of the signal transduction pathways of tumorigenesis,  expertise in synthetic chemistry,  and insight into the tumor microenvironment.  

Our goal is to become an efficient drug innovation engine to create and sustain a pipeline of breakthrough medicines that are  efficacious and accessible to patients worldwide.

Core Values


Respect for people is at the very core of our values. We are committed to providing a nourishing environment for employees to discover their passions, unleash their creativities and realize their full potentials.


Integrity is the foundation for a scientific enterprise and the most basic requirement for Tyligand team members. We believe success will only come only if we insist on seeking the truth.


Innovation is not only our core competency but also the reason for our being. We believe that every problem plaguing the humanity has a solution to be discovered or optimized.  We strive to build a win-win platform for the open minded and the persistent scientists to connect, challenge each other, test hypotheses and co-create answers that matter.


We will always bear in mind the responsibilities that come with the power of science in our hands, and the commitments made to our families, coworkers, investors, partners, patients, the environment, and the society.   

Tyligand Milestones

May 2018

Founded in 2018

Founders include seasoned pharma executives, experienced drug hunter with stellar track record, and leading international authority on protein phosphatase research

May 2018

Dec 2019

Seed Funding

Oriza Holdings, Med-Fine Capital, Bohe Angel and K2VC 

Apr 2021

Series A Funding

VI Ventures, Yijing Investment and CMS (China Medical System) 

Apr 2021

Mar 2022

TSN084 Clinical Trial

TSN084 achieved First Patient Dose in the US

Oct 2022

ADC Payload Design and Development

Collaborated with GeneQuantum and delivered novel payloads for ADC development

Oct 2022

Dec 2022


TSN222 IND Clearance from US FDA

Feb 2023


TSN222 IND Clearance from China NMPA

Feb 2023

Jul 2023

Series A+ Funding

Ming Ventures, CMS, Taikun Fund, Suzhou Harvicapital, Shengdi Investments, BOHE Angel Fund and Calor Capital

Jul 2023

TSN222 Clinical Trial

TSN222 Achieved First Patient Dose in China

Jul 2023